Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Oct 31;14(10):2414-2416.
doi: 10.21037/tp-2025-572. Epub 2025 Oct 28.

Advancing the treatment of NTRK-fused pediatric solid tumors: lessons from the ADVL1823 study

Carolina Sgarioni Camargo Vince  1   2 , Elvis Terci Valera  3
Affiliations
Editorial

Advancing the treatment of NTRK-fused pediatric solid tumors: lessons from the ADVL1823 study

Carolina Sgarioni Camargo Vince et al. Transl Pediatr. .
No abstract available

Keywords: NTRK fusions; infantile fibrosarcoma (IFS); larotrectinib; pediatric oncology; tissue-agnostic therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-2025-572/coif). C.S.C.V. reports consulting and advisory role in Bayer. E.T.V. reports consulting or advisory role in Pfizer and Bayer. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Laetsch TW, Voss S, Ludwig K, et al. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). J Clin Oncol 2025;43:1188-97. 10.1200/JCO-24-01854 - DOI - PMC - PubMed
    1. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016;1:e000023. 10.1136/esmoopen-2015-000023 - DOI - PMC - PubMed
    1. Kummar S, Lassen UN. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy. Target Oncol 2018;13:545-56. 10.1007/s11523-018-0590-1 - DOI - PubMed
    1. Percy C, Schubert T, Galant C, et al. Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report. Clin Case Rep 2021;9:1694-8. 10.1002/ccr3.3878 - DOI - PMC - PubMed
    1. Sahni S, Rastogi S, Yadav R, et al. Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib. Ecancermedicalscience 2023;17:1575. 10.3332/ecancer.2023.1575 - DOI - PMC - PubMed